OCAST FY24 Applications: The only OCAST programs to have funding for award in FY2024 (July 1, 2023 – June 30, 2024) are the Oklahoma Applied Research Support (OARS) program and the Intern Partnership program.  The OCAST Health Research, Health Research Fellowship and Plant Science programs will go unfunded in FY2024.  Please note projects supporting industry in the three targeted strategic areas with the greatest probability of maximum return, Biotech/life sciences (including Ag-Tech), aerospace/autonomous systems and defense, and energy diversification are eligible for the OARS program.  The OARS program in FY2024 will not offer proof-of-concept funding. Applications are open August 2^nd.

 

OCAST Information Session: Learn How to Submit a Qualifying Application

You'll gain valuable insights on the application process, discover what’s new with the Oklahoma Applied Research Support (OARS) and the Intern Partnership Program. Whether you're a seasoned or new to the OCAST’s FOA program, this session will equip you with the knowledge and tools to enhance your application.

Highlights of the Information Session:

• Detailed walkthrough of the application process
• Introduction to OARS and its latest enhancements
• Overview of the Internship program
• Q&A session to address all your queries

Join on your computer, mobile app or room device
https://lnkd.in/dtyQXCi9
Meeting ID: 252 388 021 933
Passcode: kCScbu
Join with a video conferencing device
831653214@t.plcm.vc
Video Conference ID: 112 322 750 1

 

OK Symposium on Pancreatic Cancer Cachexia
OU Health Stephenson Cancer Center is proud to host the OK Symposium on Pancreatic Cancer Cachexia on August 25-26, 2023 at the Colcord Hotel in Oklahoma City.
The purpose of this symposium is to advance the understanding of the basis of pancreatic cancer cachexia and enhance research collaborations on pancreatic cancer. Pancreatic cancer and cancer cachexia are under-studied areas that have drawn much attention in the last few years. Funded by the Presbyterian Health Foundation and the NCI designated OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, this multidisciplinary symposium will provide a unique opportunity to catalyze interactions among invited speakers and local investigators through sharing ideas, research discoveries, and challenges towards advancing the field of pancreatic cancer cachexia. The meeting will highlight speakers from many premier research institutions in the nation, and local speakers from several institutions within the state. The topics to be covered will feature cutting edge technologies, new animal models and novel discoveries on pancreatic cancer cachexia. Specifically: muscle wasting, adipose loss, cross talk between muscle and adipose and tumor cells, inflammation, metabolism, extracellular vesicles, microRNAs, cytokines, and pancreatic cancer metastasis.

Register: OK Symposium on Pancreatic Cancer Cachexia
Contact: Emily Hulseberg emily-hulseberg@ouhsc.edu

 

Investigator Initiated Trials Funding Committee (IITFC), Clinical Trials Office-Protocol Support Unit

Description: Grant proposals are being accepted for the 2023 Fall cycle from Stephenson Cancer Center Providers for their investigator-initiated clinical trials (IITs) or translational work for the amount of up to $100,000 for clinical trials, and up to $25,000 for translation research. All applications should be submitted to the Protocol Support Unit at SCC-IIT-Office@ouhsc.edu and should adhere to the Grant template and Submission Checklist provided with this notice. Investigators should request the budget template from the CTO Budget Manager (ClinicalTrialBudgets@ouhsc.edu).  

Deadline: October 9, 2023 

Link to the full announcement or a flier: Please refer to the attached flyer for additional funding criteria and details.

 

Once-a-year NIH SBIR Contract Solicitation from NIH (PHS-2024-1)

Any OUHSC researcher interested in commercializing their research should look at this once-a-year solicitation.  It relates to one of the following specific areas listed below. The once-a-year NIH SBIR Contract Solicitation will soon be coming out and from prior experience of other investigators it is often the single easiest SBIR award mechanism to get a fundable score. This is not the normal, more academic NIH SBIR, the contract proposals don’t go through the Center for Scientific Review (CSR).  The awards directly fund what NIH program managers want to fund. So if, you are interested in launching a startup, securing SBIR funding, and there is a topic in the list below that matches your area of interest, this could be a great opportunity. If any faculty are interested they can contact John Hanak (jhanak@ou.edu), the Chief Innovation and Corporate officer that oversees these activities on the OUHSC, OU-Norman, and OU-Tulsa campuses. He will be able to get you in touch with the OK Catalyst team and they will help you through the process.  

THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2024-1

NATIONAL INSTITUTES OF HEALTH (NIH)
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS):
Topic 024 - Small Manufacturing Systems to Produce Research Grade Pharmaceutical Intermediates
NATIONAL CANCER INSTITUTE (NCI):
Topic 455 - Point-of-Care Detection of Prostate Specific Antigen
Topic 456 - Rapid and Affordable Point-of-Care HPV Diagnostics for Cervical Cancer Control
Topic 457 - Technologies for Detecting Tumor-Derived Cell Clusters
Topic 458 - Microbiome-Based Tests for Cancer Research, Diagnosis, Prognosis and/or Patient Management
Topic 459 - Automated Software for Point-of-Care Testing to Identify Cancer-Associated Malnutrition
Topic 460 - Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies
Topic 461 - Ultra-Fast Dose Rate (FLASH) Radiation Detectors and Safety Systems for Cancer Treatment
Topic 462 - Organ-on-Chip for Preclinical and Translational Radiobiological Studies
Topic 463 - Translation of Novel Cancer-specific Imaging Agents and Techniques to Mediate Successful Image-guided Cancer Interventions
Topic 464 - Cloud-Based Multimodal Data Analysis Software for the Cancer Research Data Commons
Topic 465 - Cancer Prevention and Treatment Clinical Trials Tools for Recruitment and Retention of Diverse Populations
NATIONAL INSTITUTE ON AGING (NIA): 
Topic 010 - Technology to facilitate characterization of the exosome in under –resourced populations for AD/ADRD Studies
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID):
Topic 124 - Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV-1 Broadly Neutralizing Antibodies
Topic 125 - Development of Long-Acting Treatments for HCV Cure
Topic 126 - Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection
Topic 127 - Multiplexed Patient Administered Diagnostics for Hepatitis B, Hepatitis C, and HIV
Topic 128 - Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases
Topic 129 - Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models
Topic 130 - Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases
Topic 131 - Development of Bacteriophage for Treatment of Mycobacterial Infections
Topic 132 - Novel Diagnostic Biomarker Discovery and Validation for Malaria and Select Neglected Tropical Diseases (NTDs)
Topic 133 - Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections
Topic 134 - Alternatives to Benzathine Penicillin for Treatment of Syphilis
Topic 135 - Software or Web Services to Automate Metadata Enrichment and Standardization for Data on Infectious and Immune – Mediated Diseases
Topic 136 - Software or Web Services to Re-Represent Existing Scientific Data and Knowledge into a Knowledge Graph Format
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI):
Topic 115 - Clinical Instrument for Para-Hydrogen (pH2) Based Signal Amplification by Reversible Exchange (SABRE) for Hyperpolarizing 13C-Pyruvate and Other Probes for MRI Imaging
NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH):
Topic 001 - Point-of-Care HIV Viral Load and Drug Adherence Assays
Topic 002 - Development of novel In-vitro and In-vivo Models to support NeuroHIV Research

 

Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

• EuroFarma, a Brazilian pharmaceutical company, is seeking antimicrobial small molecules from natural sources for drugs/therapies.  Of particular interest are small molecules, both natural products and their derivatives, that target gram-negative and ESKAPE pathogens or other pathogens related to antimicrobial resistance.  Approaches that target Candida, Aspergillus fumigatus, Gram positive bacteria and human cytomegalovirus, RSV and rhinovirus will also be considered.  Out of scope are nucleic acids and proteins, and non-molecular approaches such as probiotics or phytotherapeutic medicines. Submission entails a one-page 200-300 word non-confidential brief. (deadline 08/10).
• A pharmaceutical company focused on women’s health is seeking novel druggable targets and drug candidates in the area of obstetrics and gynecology for in-licensing or early collaboration, including research project/PhD funding.  All mechanisms of action are of interest with examples being anti-fibrotic effect, ovulation failure, hormone replacement and osteoporosis. Open to different modalities with small molecule and peptides of highest interest.  Novel screening methods to identify targets and research related to novel contraceptives are also of interest.  Submission entails a one-page 200-300 word non-confidential brief. (deadline 08/19). 
• Procter & Gamble is seeking synthetic biology expertise and approaches for production of platform chemicals, surfactants, chelants, polymers and perfume raw materials and enzymes for use in the fabric, home care and beauty industries. Open to any novel and scalable synthetic biology approaches that can be applied to make production processes more sustainable and cost-effective; specific interest in C1/C2 chemistry (platform chemicals) and long chain C-12-14 nd C16-18 chemistry (e.g. long chain fatty acids/alcohols and oils. Submission entails a one-page 200-300 word non-confidential brief. (deadline 08/19). 
• A worldwide manufacturing company is seeking alternative chemistries to liquid PFAS, specifically PFPE, PFAE and fluorosilicones.  Ideally these chemicals will be sustainable, cost-effective and high-performance alternatives.  Key performance features include lubricity, wide temperature performance, oxidative stability, anti-wear and material compatibility.  Solid lubricants are out of scope.  Submission entails a one-page 200-300 word non-confidential brief. (deadline 08/25). 

 

NOTE: If the project is selected to move forward with a full application, it will need to be routed through SoonerTrack II.

 

• Review Integrity and Bias Awareness Training will be Required for NIH Reviewers Effective May 2024 Council Round
  (NOT-OD-23-156)
• Notice of NCCIH Technical Assistance Webinar and Teaming Webinar for RFA-AT-22-003 "HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required)"
  (NOT-AT-24-010)
• Notice of Prize Competition for the DataWorks! - NIH FASEB Challenge
  (NOT-OD-23-151)
• Request for Information (RFI): Inviting Input Regarding NIDCDs Research Directions to Support Communication in Minimally Verbal/Non-Speaking People
  (NOT-DC-23-013)
• Request for Information (RFI): Infrastructure for Research in Nonhuman Primates
  (NOT-OD-23-150)
• Request for Information (RFI) on Flexibilities for Streamlining IACUC Review of Protocols and Significant Changes
  (NOT-OD-23-152)
• Request for Information (RFI) on an Update to the Current OLAW Guidance Disclaimer
  (NOT-OD-23-157)
• Notice of Correction to Award Budget in RFA-CA-23-027 "Advancing Cancer Control Equity Research through Transformative Solutions Coordination Center (U24 Clinical Trial Optional)"
  (NOT-CA-23-077)
• Notice of Change to the Composition of the Advisory Committee in PAR-23-063 "Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 - Clinical Trial Optional)"
  (NOT-GM-23-047)
• Notice of Expiration of NOT-GM-22-009 Notice of Special Interest (NOSI): Administrative Supplements to Support Undergraduate Summer Research Experiences
  (NOT-GM-23-048)
• Notice of Corrected Application Forms for RFA-HG-22-027, Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional)
  (NOT-HG-23-046)
• Notice of NINR Participation in PAR-23-166, Native American Research Centers for Health (NARCH) (S06 Clinical Trial Optional)
  (NOT-NR-23-013)
• Notice of Intent to Publish a Funding Opportunity Announcement for Approaches to Identifying Preteen Suicide Risk and Protective Factors (R01 Clinical Trial Not Allowed)
  (NOT-MH-23-335)
• Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for Approaches to Identifying Preteen Suicide Risk and Protective Factors (U24 Clinical Trial Not Allowed)
  (NOT-MH-23-336)
• Notice of Intent to Publish a Notice of Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
  (NOT-NS-23-091)
• Notice of Intent to Publish a Notice of Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
  (NOT-NS-23-093)
• Notice of Special Interest: Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Admin Supp)
  (NOT-NS-23-092)
   

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

 

• PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
  (PA-23-230)
  Application Receipt Date(s): Multiple dates, see announcement.
• PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
  (PA-23-231)
  Application Receipt Date(s): Multiple dates, see announcement.
• PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
  (PA-23-232)
  Application Receipt Date(s): Multiple dates, see announcement.
• PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
  (PA-23-233)
  Application Receipt Date(s): Multiple dates, see announcement.
• Limited Competition: Centers of Biomedical Research Excellence (COBRE) (Phase 3) - Transitional Centers (P30 Clinical Trial Optional)
  (PAR-23-216)
  Application Receipt Date(s): Multiple dates, see announcement.
• SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
  (PAR-23-219)
  Application Receipt Date(s): Multiple dates, see announcement.
• SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)
  (PAR-23-220)
  Application Receipt Date(s): Multiple dates, see announcement.
• Research Resource for Systematic Reviews of Complementary and Integrative Health (R24 Clinical Trial Not Allowed)
  (RFA-AT-24-005)
  Application Receipt Date(s): August 31, 2023
• Limited Competition for the Continuation of Cure Glomerulonephropathy (CureGN) Participating Clinical Centers (U01 Clinical Trial Not Allowed)
  (RFA-DK-22-512)
  Application Receipt Date(s): October 19, 2023
• Single Source for the Continuation of Cure Glomerulonephropathy (CureGN) Data Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-DK-22-513)
  Application Receipt Date(s): October 19, 2023
• Single Source: NIH Blueprint for Neuroscience Research: NeuroImaging Tools and Resources Collaboratory (R24 Clinical Trial Not Allowed)
  (RFA-EB-23-007)
  Application Receipt Date(s): September 26, 2023
• Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clinical Trial Not Allowed)
  (RFA-HL-24-006)
  Application Receipt Date(s): October 27, 2023
• Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordinating Center (U24- Clinical Trial Not Allowed)
  (RFA-HL-24-007)
  Application Receipt Date(s): October 27, 2023
• Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed)
  (RFA-HL-24-012)
  Application Receipt Date(s): October 27, 2023
• Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical High Risk for Psychosis Clinical Trial Network (U01 Clinical Trial Required)
  (RFA-MH-24-150)
  Application Receipt Date(s): October 17, 2023
• Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed)
  (RFA-MH-24-151)
  Application Receipt Date(s): October 17, 2023
• Partnerships With Common Fund Data Ecosystem Resources (U24 Clinical Trial not Allowed)
  (RFA-RM-23-013)
  Application Receipt Date(s): December 04, 2023

 

DoD Breast Cancer Research Program (https://cdmrp.health.mil/funding/bcrp)

Clinical Research Extension Award II (CREA2-2)

• Pre-Application (Letter of Intent) deadline: September 12, 2023
• Application deadline: September 26, 2023

 

DoD Breast Cancer Research Program (https://cdmrp.health.mil/funding/bcrp)

Breakthrough Award Levels 1 and 2

• Pre-application submission deadline: July 25, 2023 5:00 p.m. Eastern Time
• Full application submission deadline: August 8, 2023 11:59 p.m. Eastern Time

Era of Hope Scholar Award

• Pre-application submission deadline: July 25, 2023 5:00 p.m. Eastern Time
• Full application submission deadline: August 8, 2023 11:59 p.m. Eastern Time

Transformative Breast Cancer Consortium Development Award

• Pre-application submission deadline is July 25, 2023 5:00 p.m. Eastern Time
• Full application submission deadline is August 8, 2023 11:59 p.m. Eastern Time

 

DoD Lung Cancer Research Program (https://cdmrp.health.mil/funding/lcrp)

Patient-Centered Outcomes and Survivorship Award

• Pre-application submission deadline is July 20, 2023 5:00 p.m. Eastern Time
• Full application submission deadline is August 10, 2023 11:59 p.m. Eastern Time

Idea Development Award

• Full application submission deadline is August 3, 2023 11:59 p.m. Eastern Time

Translational Research Award

• Full application submission deadline is August 3, 2023 11:59 p.m. Eastern Time

 

DoD Peer Reviewed Cancer Research Program (https://cdmrp.health.mil/funding/prcrp)

Career Development Award – Fellow and Resident Options

• Pre-application submission deadline is July 25, 2023 5:00 p.m. Eastern Time
• Full application submission deadline is August 10, 2023 11:59 p.m. Eastern Time

Patient Well-Being and Survivorship Award

• Pre-application submission deadline: July 25, 2023 5:00 p.m. Eastern Time
• Full application submission deadline: August 10, 2023 11:59 p.m. Eastern Time

Translational Team Science Award

• Pre-application submission deadline: July 25, 2023 5:00 p.m. Eastern Time
• Full application submission deadline: August 10, 2023 11:59 p.m. Eastern Time

 

Advanced Research Projects Agency for Health (ARPA-H) Open Broad Agency Announcement (BAA)

Description: The mission of ARPA-H is to accelerate better health outcomes for everyone by supporting the development of high-impact solutions to society's most challenging health problems. Awardees will develop groundbreaking new ways to tackle health-related challenges through highpotential, high-impact biomedical and health research. With a scope spanning the molecular to the societal, ARPA-H seeks proposals that aim to rapidly achieve better health outcomes across patient populations, communities, diseases, and health conditions, including in support of the Cancer Moonshot. Proposals are expected to use innovative approaches to enable revolutionary advances in science, technology, or systems.
Abstract deadline: March 14, 2024
Link to Full Announcement: https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view#general

 

Oklahoma Center for Respiratory and Infectious Diseases (OCRID) Call for Proposals 2023-2024 Pilot Project Grants

Description: The purpose of the pilot project grant program is to provide seed funding to generate preliminary data for an extramural research grant application. Applicants must propose a project that fits into the central theme of the OCRID research areas, i.e., infectious diseases of the respiratory system and associated complications. Projects that use OCRID research cores (Animal Model Core, Immunopathology Core and Molecular Biology Core) are highly encouraged, as are projects that incorporate novel and advanced technologies, including, but not limited to, single-cell and spatial transcriptomics, cell-specific knockout/transgene, cell lineage tracing, machine learning/AI, organoids and stem cell technologies, human lung cell and tissue models, etc. OCRID also encourages applicants to consider the unique opportunities of having several Core-provided services in (A)BSL-3 settings. OCRID and its associated Cores will also provide infrastructure and research guidance to pilot project applicants and awardees as needed to help develop their projects.
Application deadline: August 1, 2023
Link to Full Announcement: Please refer to the attached flyer.

 

The Robert Wood Johnson Foundation’s (RWJF): Health Data for Action (Data Access Award)

Description: Access to rich data is a cornerstone of producing timely and objective research. Data can build evidence that leads to a fair and just opportunity for health, for all.  A new call for proposals offers no-cost access to timely, relevant, inclusive data that inform policy to make healthcare more affordable and equitable. Health Data for Action will award successful applicants with access to data sets to support innovative research that answers important research questions and inform health policy. Data include electronic health record and clinical data; claims and encounter data; and transparency in coverage data. First-time principal investigators will receive funding up to $100,000 per project.
Applications Deadline: August 18, 2023
Link to Full Announcement: https://www.rwjf.org/en/grants/active-funding-opportunities/2023/health-data-for-action-data-access-award.html?rid=0032S00002ZyzqpQAB&et_cid=2196580

 

The International Center for Responsible Gaming (ICRG): Grant Support for Research on Responsible Gambling and Prevention of Gambling Disorder

Description: The International Center for Responsible Gaming (ICRG) invites investigators to apply for a grant to study responsible gambling and prevention strategies designed to reduce gambling-related harms. Although a variety of topics are welcome, the safety and efficacy of Voluntary Self-Exclusion is a priority. Applicants may request up to $60,000 per year in direct costs for up to three years plus 15 percent in Facilities & Administration costs. The ICRG will support one grant award under this initiative, which was made possible by support from GeoComply.
Application Deadline: October 16, 2023
Link to Full Announcement: https://www.icrg.org/information/apply-for-icrg-funding